Business, energy, technology, markets and global industry news from Business News Today

Decipher Prostate

PharmaDeviceNews Decipher Prostate
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Medical Devices & Diagnostics

Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?

Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.

Read More
Medical Devices & Diagnostics

Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics

Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.

Read More